Finding drugs to improve the quality of life for patients with endocrine diseases with few or no treatment options, can be a noble but resource-intensive task. For Ann Arbor-based Millendo Therapeutics, a $62 million Series B financing announced in January 2016 moved the biotechnology company a little closer to that goal and earned it the […]